Hengrui Pharmaceuticals and Kailera Therapeutics reported strong Phase III efficacy for their injectable GLP-1/GIP dual receptor agonist in China, showing approximately 18% mean weight loss over 48 weeks with a favorable safety profile. Hengrui plans to file for approval domestically while Kailera prepares global trials with higher doses and longer treatment durations. The drug joins a growing wave of China-originated candidates reshaping obesity treatment pipelines worldwide.